Zhou Hao, Wang Nuan, Xu Lei, Huang Hongli, Yu Chunyu
Department of Neurology, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.
Department of Pharmacy, The First People's Hospital of Xuzhou, Xuzhou, Jiangsu 221000, P.R. China.
Exp Ther Med. 2017 Nov;14(5):4801-4806. doi: 10.3892/etm.2017.5116. Epub 2017 Sep 14.
This study evaluated the efficacy of gastrodin in combination with folate (FOL) and vitamin-B12 (V-B12) on patients with epilepsy after stroke (EAS) and its effect on high-mobility group protein B1 (HMGB-1), interleukin-1 (IL-1), and IL-6 serum levels. The clinical data of 92 EAS patients admitted for treatment between April, 2014 and March, 2016 were collected. These patients were randomly divided into control and observation groups (n=46 each) using computer software. Patients in the control group were administered only regular antiepileptic drugs, whereas observation group patients also received a combination of gastrodin, FOL and V-B12. After treatment, we compared efficacy, frequency of epileptic seizure, and Montreal cognitive assessment (MoCA) scores. Serum homocysteine (HCY), FOL and V-B12 levels were detected 3 months later. Enzyme-linked immunosorbent assay (ELISA) was used to detect changes in serum HMGB-1, IL-2 and IL-6 levels at one day before treatment and on the 7th, 21st, 30th and 90th days after treatment. Pearson's correlation coefficient was utilized to analyze the correlations of HMGB-1 with IL-2 and IL-6. The total treatment effectiveness rate was 95.65% in the observation group, which was significantly higher than the control group (73.91%, p<0.05). Epileptic seizure frequency and MoCA scores significantly improved in the observation group (p<0.05). Serum HCY levels were significantly lower, whereas FOL and V-B12 serum levels were significantly higher, at 3 months post-treatment start in the observation group relative to control group (p<0.05). After treatment, serum HMGB-1, IL-2 and IL-6 levels progressively decreased over time in both groups, but observation group levels were significantly lower than in control group (p<0.05). Pearson's correlation coefficient analysis showed that HMGB-1 levels were positively correlated with IL-2 and IL-6 levels. A combination of gastrodin, FOL and V-B12 for EAS can significantly improve inflammatory response symptoms, decrease HCY levels, and increase FOL and V-B12 levels in serum while effectively controlling epileptic seizures, thus exhibiting relatively better clinical efficacy. Therefore, this combination treatment is worthy of being promoted in clinical practice.
本研究评估了天麻素联合叶酸（FOL）和维生素B12（V-B12）对脑卒中后癫痫（EAS）患者的疗效及其对高迁移率族蛋白B1（HMGB-1）、白细胞介素-1（IL-1）和IL-6血清水平的影响。收集了2014年4月至2016年3月期间收治的92例EAS患者的临床资料。使用计算机软件将这些患者随机分为对照组和观察组（每组n = 46）。对照组患者仅给予常规抗癫痫药物，而观察组患者还接受天麻素、FOL和V-B12的联合治疗。治疗后，比较疗效、癫痫发作频率和蒙特利尔认知评估（MoCA）评分。3个月后检测血清同型半胱氨酸（HCY）、FOL和V-B12水平。采用酶联免疫吸附测定（ELISA）法检测治疗前1天及治疗后第7、21、30和90天血清HMGB-1、IL-2和IL-6水平的变化。利用Pearson相关系数分析HMGB-1与IL-2和IL-6的相关性。观察组的总治疗有效率为95.65%，显著高于对照组（73.91%，p<0.05）。观察组的癫痫发作频率和MoCA评分显著改善（p<0.05）。与对照组相比，观察组治疗开始后3个月时血清HCY水平显著降低，而血清FOL和V-B12水平显著升高（p<0.05）。治疗后，两组血清HMGB-1、IL-2和IL-6水平均随时间逐渐降低，但观察组水平显著低于对照组（p<0.05）。Pearson相关系数分析表明，HMGB-1水平与IL-2和IL-6水平呈正相关。天麻素、FOL和V-B12联合治疗EAS可显著改善炎症反应症状，降低HCY水平，提高血清FOL和V-B12水平，同时有效控制癫痫发作，从而表现出相对较好的临床疗效。因此，这种联合治疗值得在临床实践中推广。
